Kyowa Kirin Co Ltd 2024 Integrated Report
The report presents 2024 as a year of strategic execution, including completion of the Orchard Therapeutics acquisition and expansion of gene and cell therapy capabilities. It reports consolidated revenue of ¥495,558 million and 5,669 employees at year-end. Environmental priorities include a 55% Scope 1+2 reduction target by 2030 and net-zero GHG emissions across the value chain by 2050. The report also describes a new CEO/COO structure and progress in digital transformation.
Company: Kyowa Kirin Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2024
Type: Integrated Report
Pages: 74
Back to company
Kyowa Kirin Co Ltd
Integrated Report
The report presents 2024 as a year of strategic execution, including completion of the Orchard Therapeutics acquisition and expansion of gene and cell therapy capabilities. It reports consolidated revenue of ¥495,558 million and 5,669 employees at year-end. Environmental priorities include a 55% Scope 1+2 reduction target by 2030 and net-zero GHG emissions across the value chain by 2050. The report also describes a new CEO/COO structure and progress in digital transformation.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees